FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C. 20549
---------------	------------

Check this box if no longer subject					
to Section 16. Form 4 or Form 5					
obligations may continue. See					
Instruction 1(b).					

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Miller Mary				2. Issuer Name and Ticker or Trading Symbol Acrivon Therapeutics, Inc. [ACRV]										ck all app Direc	tor 10% Owne		wner			
(Last)	`	irst) (I	Middle)			Date of Earliest Transaction (Month/Day/Year) 2/14/2024										Officer (give title Other (specify below) Chief Legal Officer				
480 ARSENAL WAY, SUITE 100				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	l ''							
(Street) WATERTOWN MA 02472														X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)							Rule 10b5-1(c) Transaction Indication													
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	3ene	ficiall	y Own	ed				
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)				Exe ay/Year) if ar		Deemed ecution Date, any onth/Day/Year)		3. Transaction Code (Instr. 8) 4. Securitie Disposed (5) 5)			es Acquired (A Of (D) (Instr. 3,				ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)		Price	Transa	eported ansaction(s) nstr. 3 and 4)			(Instr. 4)	
Common Stock 02/14/					2024				F ⁽¹⁾		217	I)	\$3.4	40	40,451		D		
		Та									osed of, o				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed on Date, (Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (Ir	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amo or Num of Shar	ber						

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

/s/ Rasmus Holm-Jorgensen, 02/16/2024 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.